Valutazione economica dell'uso dell'abciximab come preparazione all'angioplastica coronarica nel contesto sanitario Italiano

Translated title of the contribution: Economic evaluation of abciximab in the per-treatment of patients undergoing percutaneous transluminal coronary angioplasty in the context of the Italian health-care system

Roberto Lorenzoni, Gianfranco Mazzotta, Gian Franco Gensini, Raffaele De Caterina

Research output: Contribution to journalArticle

Abstract

Drugs blocking platelet glycoprotein IIb/IIIa receptors (anti-GP IIb/IIIa) have been used effectively to prevent thrombotic events after percutaneous transluminal coronary angioplasty (PTCA). However, the high cost of these drugs calls for an economic evaluation before they can be used systematically within the context of the Italian health-care system. METHODS. The systematic review of three studies (EPIC EPILOG, CAPTURE) that evaluated the effectiveness of abciximab (the only anti-GP IIb/IIIa drug commercially available in Italy) demonstrated that this drug can prevent thrombotic events (death, myocardial infarction, repeated PTCA, bypass surgery) at six months after PTCA (RR 0.84; IC 95% 0.77-0.91; number needed to treat for the composite end-point 21). We performed an economic evaluation of the use of abciximab, taking into account the cost the drug (2 561 100 Italian lire [ITL]/patient) and the number of events prevented. We calculated the mean cost-effectiveness ratio (cost of each patient without events at six months after PTCA), the incremental cost-effectiveness ratio (cost of each event prevented at six months after PTCA) and the cost of each year of life saved at six months after PTCA. RESULTS. The mean cost-effectiveness ratio was 16.6 million ITL/patient (versus 15.4 million ITL/patient without the use of the drug); the incremental cost-effectiveness ratio was 34.3 million ITL/event prevented; the cost of each year of life saved was 32.3 million ITL. CONCLUSIONS. With abciximab preventing thrombotic events at six months after PTCA, the cost of each patient without events and the cost of each event prevented at six months are within the range of other pharmaceutical procedures in cardiology (e.g. thrombolysis in acute myocardial infarction with tissue plasminogen activator). Our analysis supports the case for the systematic use of abciximab in patients undergoing PTCA.

Original languageItalian
Pages (from-to)269-276
Number of pages8
JournalGiornale Italiano di Cardiologia
Volume29
Issue number3
Publication statusPublished - Mar 1999

Fingerprint

Coronary Balloon Angioplasty
Cost-Benefit Analysis
Delivery of Health Care
Costs and Cost Analysis
Platelet Membrane Glycoprotein IIb
Drug Costs
Pharmaceutical Preparations
Therapeutics
Myocardial Infarction
Integrin beta3
Numbers Needed To Treat
Platelet Glycoprotein GPIIb-IIIa Complex
abciximab
Tissue Plasminogen Activator
Cardiology
Italy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Valutazione economica dell'uso dell'abciximab come preparazione all'angioplastica coronarica nel contesto sanitario Italiano. / Lorenzoni, Roberto; Mazzotta, Gianfranco; Gensini, Gian Franco; De Caterina, Raffaele.

In: Giornale Italiano di Cardiologia, Vol. 29, No. 3, 03.1999, p. 269-276.

Research output: Contribution to journalArticle

Lorenzoni, Roberto ; Mazzotta, Gianfranco ; Gensini, Gian Franco ; De Caterina, Raffaele. / Valutazione economica dell'uso dell'abciximab come preparazione all'angioplastica coronarica nel contesto sanitario Italiano. In: Giornale Italiano di Cardiologia. 1999 ; Vol. 29, No. 3. pp. 269-276.
@article{6044f2d88e4b468b831139e2d83d926c,
title = "Valutazione economica dell'uso dell'abciximab come preparazione all'angioplastica coronarica nel contesto sanitario Italiano",
abstract = "Drugs blocking platelet glycoprotein IIb/IIIa receptors (anti-GP IIb/IIIa) have been used effectively to prevent thrombotic events after percutaneous transluminal coronary angioplasty (PTCA). However, the high cost of these drugs calls for an economic evaluation before they can be used systematically within the context of the Italian health-care system. METHODS. The systematic review of three studies (EPIC EPILOG, CAPTURE) that evaluated the effectiveness of abciximab (the only anti-GP IIb/IIIa drug commercially available in Italy) demonstrated that this drug can prevent thrombotic events (death, myocardial infarction, repeated PTCA, bypass surgery) at six months after PTCA (RR 0.84; IC 95{\%} 0.77-0.91; number needed to treat for the composite end-point 21). We performed an economic evaluation of the use of abciximab, taking into account the cost the drug (2 561 100 Italian lire [ITL]/patient) and the number of events prevented. We calculated the mean cost-effectiveness ratio (cost of each patient without events at six months after PTCA), the incremental cost-effectiveness ratio (cost of each event prevented at six months after PTCA) and the cost of each year of life saved at six months after PTCA. RESULTS. The mean cost-effectiveness ratio was 16.6 million ITL/patient (versus 15.4 million ITL/patient without the use of the drug); the incremental cost-effectiveness ratio was 34.3 million ITL/event prevented; the cost of each year of life saved was 32.3 million ITL. CONCLUSIONS. With abciximab preventing thrombotic events at six months after PTCA, the cost of each patient without events and the cost of each event prevented at six months are within the range of other pharmaceutical procedures in cardiology (e.g. thrombolysis in acute myocardial infarction with tissue plasminogen activator). Our analysis supports the case for the systematic use of abciximab in patients undergoing PTCA.",
keywords = "Costs, PTCA",
author = "Roberto Lorenzoni and Gianfranco Mazzotta and Gensini, {Gian Franco} and {De Caterina}, Raffaele",
year = "1999",
month = "3",
language = "Italian",
volume = "29",
pages = "269--276",
journal = "Giornale Italiano di Cardiologia",
issn = "0046-5968",
publisher = "Societa Italiana di Cardiologia",
number = "3",

}

TY - JOUR

T1 - Valutazione economica dell'uso dell'abciximab come preparazione all'angioplastica coronarica nel contesto sanitario Italiano

AU - Lorenzoni, Roberto

AU - Mazzotta, Gianfranco

AU - Gensini, Gian Franco

AU - De Caterina, Raffaele

PY - 1999/3

Y1 - 1999/3

N2 - Drugs blocking platelet glycoprotein IIb/IIIa receptors (anti-GP IIb/IIIa) have been used effectively to prevent thrombotic events after percutaneous transluminal coronary angioplasty (PTCA). However, the high cost of these drugs calls for an economic evaluation before they can be used systematically within the context of the Italian health-care system. METHODS. The systematic review of three studies (EPIC EPILOG, CAPTURE) that evaluated the effectiveness of abciximab (the only anti-GP IIb/IIIa drug commercially available in Italy) demonstrated that this drug can prevent thrombotic events (death, myocardial infarction, repeated PTCA, bypass surgery) at six months after PTCA (RR 0.84; IC 95% 0.77-0.91; number needed to treat for the composite end-point 21). We performed an economic evaluation of the use of abciximab, taking into account the cost the drug (2 561 100 Italian lire [ITL]/patient) and the number of events prevented. We calculated the mean cost-effectiveness ratio (cost of each patient without events at six months after PTCA), the incremental cost-effectiveness ratio (cost of each event prevented at six months after PTCA) and the cost of each year of life saved at six months after PTCA. RESULTS. The mean cost-effectiveness ratio was 16.6 million ITL/patient (versus 15.4 million ITL/patient without the use of the drug); the incremental cost-effectiveness ratio was 34.3 million ITL/event prevented; the cost of each year of life saved was 32.3 million ITL. CONCLUSIONS. With abciximab preventing thrombotic events at six months after PTCA, the cost of each patient without events and the cost of each event prevented at six months are within the range of other pharmaceutical procedures in cardiology (e.g. thrombolysis in acute myocardial infarction with tissue plasminogen activator). Our analysis supports the case for the systematic use of abciximab in patients undergoing PTCA.

AB - Drugs blocking platelet glycoprotein IIb/IIIa receptors (anti-GP IIb/IIIa) have been used effectively to prevent thrombotic events after percutaneous transluminal coronary angioplasty (PTCA). However, the high cost of these drugs calls for an economic evaluation before they can be used systematically within the context of the Italian health-care system. METHODS. The systematic review of three studies (EPIC EPILOG, CAPTURE) that evaluated the effectiveness of abciximab (the only anti-GP IIb/IIIa drug commercially available in Italy) demonstrated that this drug can prevent thrombotic events (death, myocardial infarction, repeated PTCA, bypass surgery) at six months after PTCA (RR 0.84; IC 95% 0.77-0.91; number needed to treat for the composite end-point 21). We performed an economic evaluation of the use of abciximab, taking into account the cost the drug (2 561 100 Italian lire [ITL]/patient) and the number of events prevented. We calculated the mean cost-effectiveness ratio (cost of each patient without events at six months after PTCA), the incremental cost-effectiveness ratio (cost of each event prevented at six months after PTCA) and the cost of each year of life saved at six months after PTCA. RESULTS. The mean cost-effectiveness ratio was 16.6 million ITL/patient (versus 15.4 million ITL/patient without the use of the drug); the incremental cost-effectiveness ratio was 34.3 million ITL/event prevented; the cost of each year of life saved was 32.3 million ITL. CONCLUSIONS. With abciximab preventing thrombotic events at six months after PTCA, the cost of each patient without events and the cost of each event prevented at six months are within the range of other pharmaceutical procedures in cardiology (e.g. thrombolysis in acute myocardial infarction with tissue plasminogen activator). Our analysis supports the case for the systematic use of abciximab in patients undergoing PTCA.

KW - Costs

KW - PTCA

UR - http://www.scopus.com/inward/record.url?scp=0032892225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032892225&partnerID=8YFLogxK

M3 - Articolo

C2 - 10231672

AN - SCOPUS:0032892225

VL - 29

SP - 269

EP - 276

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 0046-5968

IS - 3

ER -